As part of the TACTICS (Transnational Alliance for Regenerative Therapies in
Cardiovascular Syndromes) series to enhance regenerative medicine, here, we discuss the …

Rationale: Cardiac stem cells (CSC) therapy has been clinically introduced for cardiac repair
after myocardial infarction (MI). To date, there has been no systematic overview and meta …

Human cardiac organoids hold remarkable potential for cardiovascular disease modeling
and human pluripotent stem cell–derived cardiomyocyte (hPSC-CM) transplantation. Here …

Rationale: Virtually all mesenchymal stem cell (MSC) studies assume that therapeutic effects
accrue from local myocardial effects of engrafted MSCs. Because few intravenously …

Heart Diseases are serious and global public health concern. In spite of remarkable
therapeutic developments, the prediction of patients with Heart Failure (HF) is weak, and …

In pigs, the major histocompatibility complex (MHC), or swine leukocyte antigen (SLA)
complex, maps to Sus scrofa chromosome 7. It consists of three regions, the class I and …

Regenerating the human heart is a challenge that has engaged researchers and clinicians
around the globe for nearly a century. From the repair of the first septal defect in 1953 …

Rationale: Dual cell transplantation of cardiac progenitor cells (CPCs) and mesenchymal
stem cells (MSCs) after infarction improves myocardial repair and performance in large …

Aims Cardiomyopathy patients are prone to ventricular arrhythmias (VA) and sudden cardiac
death. Current therapies to prevent VA include radiofrequency ablation to destroy slowly …

The microenvironment plays a crucial role in the behavior of stem and progenitor cells. In the
heart, cardiac progenitor cells (CPCs) reside in specific niches, characterized by key …